<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239888</url>
  </required_header>
  <id_info>
    <org_study_id>MAPRC 2010CK</org_study_id>
    <nct_id>NCT01239888</nct_id>
  </id_info>
  <brief_title>Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study</brief_title>
  <official_title>Phase IB Study of Efficacy and Safety of Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Alfred</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Alfred</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an oxytocin ad-on, or oxytocin and tibolone
      ad-on can induce a response to antidepressants in patients with treatment resistant
      depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are examining the efficacy and safety of oxytocin or oxytocin and tibolone with an
      antidepressant (SSRIs) in treatment resistant depression in a double-blind randomized
      clinical trial.

      A secondary objective is the evaluation of neurobiological factors contributing to drug
      efficacy in treatment resistant depression.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Assessed at different time points: 1 week, 2 weeks, 4 weeks, 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hamilton Rating Scale for Depression (HAM-D)</measure>
    <time_frame>Assessed at different time points: 1 week, 2 weeks, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Beck Depression Inventory II (BDI-II)</measure>
    <time_frame>Assessed at different time points: 1 week, 2 weeks, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in State Trait Anxiety Inventory (STAI)</measure>
    <time_frame>Assessed at different time points: 1 week, 2 weeks, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Symptom Check List</measure>
    <time_frame>baseline, week 2, week 4, week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived stress scale</measure>
    <time_frame>baseline, week 2, week 4, week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh sleep quality index</measure>
    <time_frame>baseline, week 2, week 4, week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)</measure>
    <time_frame>baseline, week 2, week 4, week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin and Tibolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial</description>
    <arm_group_label>Oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin and Tibolone</intervention_name>
    <description>20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial</description>
    <arm_group_label>Oxytocin and Tibolone</arm_group_label>
    <other_name>Livial (tibolone)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women

          -  18-45 years

          -  Current DSM-IV diagnosis of Major Depression

          -  Comorbid anxiety disorders secondary to depression will be included

          -  Past history of at least 2 failed treatment responses (including SSRIs) at the highest
             tolerated dose for at least 4-6 weeks

          -  A MADRS score &gt;20 at randomization

          -  Women on a stable dose of an SSRI (sertraline, citalopram, escitalopram, paroxetine,
             fluoxetine or fluvoxamine) for at least 4-6 weeks.

          -  A negative pregnancy test at screening

          -  A clinically acceptable Pap smear within the past 2 years

          -  Must be able to use intranasal spray and swallow tablets

        Patients may take up to 2 sleep medications permitted at a dose considered reasonable by
        the investigating team. Limited adjustments in sleep medication are acceptable. Patients
        will be asked to notify the researchers of any changes to their sleep medication.

        Exclusion Criteria:

          -  Any previous history of adverse side-effects to escitalopram (or other SSRI)

          -  Use of oral contraceptives (or any hormonal method of contraception) for the duration
             of the study

          -  DSM-IV defined substance dependence, history of bipolar disorder, schizoaffective
             disorder or schizophrenia

          -  Significant unstable medical illness including epilepsy, diabetes or cardiac related,
             renal or liver disease, hormone dependent cancer or pregnancy

          -  A BMI&lt;18 or &gt; 34kg/m2

          -  Planning for pregnancy

          -  Renal disease, history of cerebrovascular disease, thrombo-embolic disorders,
             myocardial infarction or angina at any time before study entry or thrombo-phlebitis
             within the last 5 years, or any other major illness that has occurred within the last
             6 months.

          -  An undiagnosed genital bleeding

          -  Moderate to severe acne or hirsutism, have used antiandrogen therapy for acne or
             hirsutism in the preceding 5 years, have androgenic alopecia ( will exclude women with
             clinically meaningful androgen excess)

          -  Active malignancy, or treatment for malignancy in the preceding 6 months (excluding
             non-melanotic skin cancer)

          -  Alcohol consumption in excess of 3 standard drinks per day

          -  Lactose intolerance

          -  An abnormal thyroid stimulating hormone (TSH) value at screening confirmed by a Free
             T4 outside the normal laboratory range (patients with an abnormal TSH, normal Free T4
             and no clinical signs or symptoms of thyroid disease, with or without replacement
             treatment, may be admitted to the study).

          -  A history of allergic reactions to androgens (oral or patch)

          -  Chronic medications: aspirin and warfarin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Keating, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash University and the Alfred</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte Keating, PhD</last_name>
    <phone>+61 3 9076 5180</phone>
    <phone_ext>5180</phone_ext>
    <email>charlotte.keating@monash.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Monash Alfred Psychiatry Research Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Keating, PhD</last_name>
      <email>charlotte.keating@monash.edu</email>
    </contact>
    <investigator>
      <last_name>Charlotte Keating, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Fitzgerald, MBBS, MPM, FRANZCP, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jayashri Kulkarni, MBBS, MPM, FRANZCP, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan Tilbrook, BAgSc(Hons), PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony DeCastella, DipAppSci, BA, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <last_update_submitted>January 15, 2012</last_update_submitted>
  <last_update_submitted_qc>January 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Alfred</investigator_affiliation>
    <investigator_full_name>Charlotte Keating</investigator_full_name>
    <investigator_title>Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Treatment resistant depression</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Estrogen Modulators</keyword>
  <keyword>HPA axis</keyword>
  <keyword>Mental Disorders</keyword>
  <keyword>Estrogens</keyword>
  <keyword>Tibolone</keyword>
  <keyword>Estrogen Receptor Modulators</keyword>
  <keyword>Androgens</keyword>
  <keyword>Hormones</keyword>
  <keyword>Hormone Substitutes</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Hormone Antagonists</keyword>
  <keyword>Bone Density Conservation Agents</keyword>
  <keyword>Estrogen Antagonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Tibolone</mesh_term>
    <mesh_term>Bone Density Conservation Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

